GENinCode plc
GENinCode plc (GENI.L) Stock Competitors & Peer Comparison
See (GENI.L) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GENI.L | £1.80 | +0.00% | 5.2M | -0.60 | -£0.03 | N/A |
| 0QNO.L | £573.20 | -0.66% | 39.1B | 14.50 | £39.52 | +0.69% |
| 0KHE.L | £89.94 | -3.12% | 10.7B | 14.68 | £6.16 | +0.31% |
| IDHC.L | £0.36 | +0.00% | 206.4M | 8.88 | £0.04 | N/A |
| 0G8X.L | £0.46 | -1.24% | 186.1M | -0.06 | -£7.81 | N/A |
| DXRX.L | £133.50 | +0.00% | 112.8M | -66.75 | -£0.02 | N/A |
| AGL.L | £6.00 | +0.00% | 19.4M | -1.20 | -£0.05 | N/A |
| YGEN.L | £0.51 | -0.47% | 16.4M | -0.51 | -£0.01 | N/A |
| ABDX.L | £6.75 | +8.00% | 13.1M | -6.75 | -£0.01 | N/A |
| PRM.L | £3.04 | +0.00% | 9M | -3.04 | -£0.01 | N/A |
Stock Comparison
GENI.L vs 0QNO.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, 0QNO.L has a market cap of 39.1B. Regarding current trading prices, GENI.L is priced at £1.80, while 0QNO.L trades at £573.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas 0QNO.L's P/E ratio is 14.50. In terms of profitability, GENI.L's ROE is -2.25%, compared to 0QNO.L's ROE of +0.07%. Regarding short-term risk, GENI.L is more volatile compared to 0QNO.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check 0QNO.L's competition here
GENI.L vs 0KHE.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, 0KHE.L has a market cap of 10.7B. Regarding current trading prices, GENI.L is priced at £1.80, while 0KHE.L trades at £89.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas 0KHE.L's P/E ratio is 14.68. In terms of profitability, GENI.L's ROE is -2.25%, compared to 0KHE.L's ROE of +0.04%. Regarding short-term risk, GENI.L is more volatile compared to 0KHE.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check 0KHE.L's competition here
GENI.L vs IDHC.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, IDHC.L has a market cap of 206.4M. Regarding current trading prices, GENI.L is priced at £1.80, while IDHC.L trades at £0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas IDHC.L's P/E ratio is 8.88. In terms of profitability, GENI.L's ROE is -2.25%, compared to IDHC.L's ROE of +0.24%. Regarding short-term risk, GENI.L is more volatile compared to IDHC.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check IDHC.L's competition here
GENI.L vs 0G8X.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, 0G8X.L has a market cap of 186.1M. Regarding current trading prices, GENI.L is priced at £1.80, while 0G8X.L trades at £0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas 0G8X.L's P/E ratio is -0.06. In terms of profitability, GENI.L's ROE is -2.25%, compared to 0G8X.L's ROE of -5.30%. Regarding short-term risk, GENI.L is more volatile compared to 0G8X.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check 0G8X.L's competition here
GENI.L vs DXRX.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, DXRX.L has a market cap of 112.8M. Regarding current trading prices, GENI.L is priced at £1.80, while DXRX.L trades at £133.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas DXRX.L's P/E ratio is -66.75. In terms of profitability, GENI.L's ROE is -2.25%, compared to DXRX.L's ROE of -0.04%. Regarding short-term risk, GENI.L is more volatile compared to DXRX.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check DXRX.L's competition here
GENI.L vs AGL.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, AGL.L has a market cap of 19.4M. Regarding current trading prices, GENI.L is priced at £1.80, while AGL.L trades at £6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas AGL.L's P/E ratio is -1.20. In terms of profitability, GENI.L's ROE is -2.25%, compared to AGL.L's ROE of -0.66%. Regarding short-term risk, GENI.L is more volatile compared to AGL.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check AGL.L's competition here
GENI.L vs YGEN.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, YGEN.L has a market cap of 16.4M. Regarding current trading prices, GENI.L is priced at £1.80, while YGEN.L trades at £0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas YGEN.L's P/E ratio is -0.51. In terms of profitability, GENI.L's ROE is -2.25%, compared to YGEN.L's ROE of -0.06%. Regarding short-term risk, GENI.L is more volatile compared to YGEN.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check YGEN.L's competition here
GENI.L vs ABDX.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, ABDX.L has a market cap of 13.1M. Regarding current trading prices, GENI.L is priced at £1.80, while ABDX.L trades at £6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas ABDX.L's P/E ratio is -6.75. In terms of profitability, GENI.L's ROE is -2.25%, compared to ABDX.L's ROE of -0.60%. Regarding short-term risk, GENI.L is less volatile compared to ABDX.L. This indicates potentially lower risk in terms of short-term price fluctuations for GENI.L.Check ABDX.L's competition here
GENI.L vs PRM.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, PRM.L has a market cap of 9M. Regarding current trading prices, GENI.L is priced at £1.80, while PRM.L trades at £3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas PRM.L's P/E ratio is -3.04. In terms of profitability, GENI.L's ROE is -2.25%, compared to PRM.L's ROE of +0.58%. Regarding short-term risk, GENI.L is more volatile compared to PRM.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check PRM.L's competition here
GENI.L vs VRCI.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, VRCI.L has a market cap of 7.8M. Regarding current trading prices, GENI.L is priced at £1.80, while VRCI.L trades at £0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas VRCI.L's P/E ratio is -0.28. In terms of profitability, GENI.L's ROE is -2.25%, compared to VRCI.L's ROE of -1.33%. Regarding short-term risk, GENI.L is less volatile compared to VRCI.L. This indicates potentially lower risk in terms of short-term price fluctuations for GENI.L.Check VRCI.L's competition here
GENI.L vs GDR.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, GDR.L has a market cap of 7.3M. Regarding current trading prices, GENI.L is priced at £1.80, while GDR.L trades at £1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas GDR.L's P/E ratio is -0.59. In terms of profitability, GENI.L's ROE is -2.25%, compared to GDR.L's ROE of -1.75%. Regarding short-term risk, GENI.L is more volatile compared to GDR.L. This indicates potentially higher risk in terms of short-term price fluctuations for GENI.L.Check GDR.L's competition here
GENI.L vs LLA.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, LLA.L has a market cap of 1.3M. Regarding current trading prices, GENI.L is priced at £1.80, while LLA.L trades at £5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas LLA.L's P/E ratio is -0.42. In terms of profitability, GENI.L's ROE is -2.25%, compared to LLA.L's ROE of N/A. Regarding short-term risk, GENI.L is less volatile compared to LLA.L. This indicates potentially lower risk in terms of short-term price fluctuations for GENI.L.Check LLA.L's competition here
GENI.L vs LLAI.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, LLAI.L has a market cap of 1.3M. Regarding current trading prices, GENI.L is priced at £1.80, while LLAI.L trades at £4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas LLAI.L's P/E ratio is -0.35. In terms of profitability, GENI.L's ROE is -2.25%, compared to LLAI.L's ROE of -0.56%. Regarding short-term risk, GENI.L is less volatile compared to LLAI.L. This indicates potentially lower risk in terms of short-term price fluctuations for GENI.L.Check LLAI.L's competition here
GENI.L vs SBI.L Comparison August 2025
GENI.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENI.L stands at 5.2M. In comparison, SBI.L has a market cap of 0. Regarding current trading prices, GENI.L is priced at £1.80, while SBI.L trades at £115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENI.L currently has a P/E ratio of -0.60, whereas SBI.L's P/E ratio is N/A. In terms of profitability, GENI.L's ROE is -2.25%, compared to SBI.L's ROE of +0.42%. Regarding short-term risk, Volatility data is not available for a full comparison. GENI.L has daily volatility of 10.53 and SBI.L has daily volatility of N/A.Check SBI.L's competition here